Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Abbott Neuromodulation's Jenn Wong discusses the TRANSCEND trial for depression, imaging tech advancing DBS and other ...

Abbott EVP Lisa Earnhardt's pay increased 19% to $6.6 million as her medical device group's sales grew by 12%.

Matt and Serena aren't on the same page about an 'incident' involving a patient in Us Weekly's exclusive clip from 'St. Denis ...

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

The future of pharmaceutical investment lies in the convergence of ESG principles with a strong emphasis on positive social ...

The most recent trading session ended with Abbott (ABT) standing at $130.28, reflecting a -1.79% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.49% gain on the day.

In an extraordinary hour that sees the Pittsburgh Trauma Medical Center flooded with victims of a mass shooting, the show ...

Experts estimate that treatment-resistant depression (TRD) impacts about 2.8 million Americans annually, and a groundbreaking ...